Mode
Text Size
Log in / Sign up

Preoperative hormonal therapy not linked to improved sperm retrieval in non-obstructive azoospermia.

Preoperative hormonal therapy not linked to improved sperm retrieval in non-obstructive azoospermia.
Photo by Galina Nelyubova / Unsplash
Key Takeaway
Consider that preoperative hormonal therapy may not improve sperm retrieval rates in non-obstructive azoospermia based on observational evidence.

This retrospective non-randomized series included 152 patients with non-obstructive azoospermia undergoing microdissection testicular sperm extraction (Micro-TESE). The study compared preoperative hormonal therapy (clomiphene citrate 25 mg daily and subcutaneous human chorionic gonadotropin 2,000 IU three times weekly for at least 3 months) to no preoperative hormonal therapy.

The primary outcome was sperm retrieval rate (SRR). Micro-TESE success (presence of viable sperm) was 50% in the non-hormonal therapy group and 45% in the preoperative hormonal therapy group, with no statistically significant difference (p = 0.53). The median follicle-stimulating hormone (FSH) level was significantly lower in the preoperative hormonal therapy group (p = 0.04), but absolute numbers were not reported.

Safety and tolerability data were not reported. Key limitations include the retrospective non-randomized design and single-center experience. The practice relevance is that preoperative hormonal therapy was not associated with a statistically significant improvement in Micro-TESE sperm retrieval outcomes in NOA patients. Causality cannot be inferred from this observational study.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionInfertility is defined as the inability to conceive after 12 months or longer of regular unprotected sexual intercourse. Azoospermia affects approximately 1% of men, with non-obstructive azoospermia (NOA) accounting for nearly 60% of cases. The role of hormonal treatment before microdissection testicular sperm extraction (Micro-TESE) in stimulating spermatogenesis in patients with NOA is controversial. From this standpoint, our study aimed to investigate the effect of preoperative hormonal treatment on sperm retrieval rates (SRRs) during Micro-TESE in NOA patients.Materials and methodsA retrospective analysis was conducted on 152 patients who underwent Micro-TESE for NOA at our center between January 2021 and December 2023. Patients were divided into two groups. The first group included patients who received preoperative hormonal therapy consisting of clomiphene citrate (25 mg daily) and subcutaneous human chorionic gonadotropin injections (2,000 IU three times weekly) for at least 3 months prior to Micro-TESE, while the second group did not. The two groups were compared for the presence of viable sperm, age, smoking status, medical illnesses (diabetes mellitus and hypertension), hormonal profile before operation [follicle-stimulating hormone (FSH), luteinizing hormone, and total testosterone], history of undescended testes, and the presence of Klinefelter syndrome. Statistical significant was defined as p-value < 0.05.ResultsA total of 152 NOA patients were included in this study, with 78 patients undergoing preoperative hormonal therapy and 74 patients not receiving any preoperative hormonal therapy. Results revealed no statistically significant differences in most demographic and clinical parameters between the groups. Hormonal analysis revealed a significantly lower median FSH level in the preoperative hormonal therapy group (p = 0.04). Micro-TESE outcomes were also comparable, with 50% success in the non-hormonal therapy group and 45% in the preoperative hormonal therapy group (p = 0.53).ConclusionIn this retrospective cohort, preoperative hormonal therapy was not associated with a statistically significant improvement in Micro-TESE sperm retrieval outcomes in NOA patients. Further studies are warranted to identify biomarkers predicting responders to preoperative hormonal stimulation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.